
Ondine Biomedical's LANTERN trial cuts surgical infections by 41%, shares up 5%.
Ondine Biomedical's phase III LANTERN trial successfully met its primary goal, showing a 41% reduction in surgical site infections within 30 days. The trial involved 5,188 patients across 18 hospitals in the US and Canada, with no significant treatme...





